Latest Pharma and Biotech News
Biotechnology
7 November 2024 According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either.
Today's issue
Refine Search
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Shanghai-based Dizal has made a submission to the US Food and Drug Administration, seeking approval for sunvozertinib. 8 November 2024
Pharmaceutical
Viracta Therapeutics has announced a significant restructuring to prioritize its lead oncology candidate, nana-val (valganciclovir/valganciclovir sodium), aimed at treating certain people with peripheral T-cell lymphoma (PTCL). 8 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Biotechnology
US healthcare giant Johnson & Johnson today revealed it has submitted applications with the US Food and drug Administration (FDA) and European Medicines Agency (EMA) to expand the approved indications for its Darzalex (daratumumab) subcutaneous (SC) formulation for the treatment of high-risk smouldering multiple myeloma (SMM). 8 November 2024
Pharmaceutical
A review has found that complexities and inefficiencies within the UK’s health data infrastructure are hindering the effective use of these resources that are critical for improving people’s health. 8 November 2024
Pharmaceutical
Italian pharma major Recordati saw its shares dip 3.75% to 50.10 euros this morning, despite posting a set of strong financial results. 8 November 2024
Biotechnology
Genmab announced during its third-quarter earnings call on Wednesday that it has discontinued three antibody programs as part of a pipeline overhaul. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Biotechnology
US biotech major Amgen and the UK’s AstraZeneca have announced positive top-line results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). 8 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Generics
US generic drugmaker Viatris announced robust financial results for the third quarter of 2024, driven by positive momentum against all three pillars of its strategy. The company’s shares shot up 13.5% to $13.18 following the announcement. 8 November 2024
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
Asklepios BioPharmaceutical (AskBio) today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug designation from the US Food and Drug Administration (FDA) for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). 7 November 2024
Biotechnology
The global market for Duchenne muscular dystrophy (DMD) therapeutics is projected to grow by $4.4 billion between 2024 and 2028, fueled by artificial intelligence and strong demand for new treatments. 7 November 2024
All news
Biotechnology
UK-based Mogrify, a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, has announced the appointment of Jonathan Appleby as chief scientific officer (CSO). 15 July 2024
Pharmaceutical
The wait for Eli Lilly's Mounjaro (tirzepatide) has got longer in India. 15 July 2024
Pharmaceutical
The number of diagnosed chronic kidney disease (CKD) cases in seven major markets is expected to rise from around 21 million to 23 million by 2033. 15 July 2024
Pharmaceutical
Spanish drugmaker PharmaMar has received a notification from the European Commission (EC) advising that it is revoking the refusal to grant a Marketing Authorization (MA) for Aplidin (plitidepsin) in multiple myeloma. 15 July 2024
Pharmaceutical
An inventory by KPMG has shown rising production of medicines in the Netherlands. 15 July 2024
Biotechnology
AbbVie on Friday revealed it has submitted applications for a new indication to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for Rinvoq (upadacitinib) 15mg, once daily for the treatment of adult patients with giant cell arteritis (GCA). 15 July 2024
Generics
India-based generic drugmaker Lupin Limited says it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for topiramate extended-release capsules. 15 July 2024
Biotechnology
M&A news last week featured US pharma major Eli Lilly announcing a $3.2 billion bid to acquire gastroenterology specialist Morphic. On the research front, US clinical-stage biotech HilleVax announced disappointing Phase IIb results with its norovirus vaccine HIL-214. Also, Dutch firm uniQure pleased investors with early--stage results for its investigational Huntington’s disease drug AMT-130, and US pharma gian
t Pfizer announced it is progressing its Parkinson’s disease candidate danuglipron. 14 July 2024
Pharmaceutical
Following its July 2024 meeting, the European Medicines Agency’s (EMA) safety committee (PRAC) has recommended new measures on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). 13 July 2024
Biosimilars
The mandate to conduct routine comparative clinical efficacy studies for biosimilar medicines, compounded by duplicative regional requirements, serves as a barrier to greater medicine access for patients, said the trade group International Generic and Biosimilar Medicines Association (IGBA). 13 July 2024
Biosimilars
South Korea’s Samsung Bioepis has released its Third Quarter 2024 Biosimilar Market Report, which includes the latest Average Sales Price (ASP) information of all biosimilars and reference products available in the US market. 12 July 2024
Biotechnology
Australian biotech Immutep has announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alfa (efti) in combination with Keytruda (pembrolizumab). 12 July 2024
Biotechnology
National Health Service (NHS) England has given approval to allow eligible patients access to Roche’s Ocrevus (ocrelizumab) subcutaneous injection for people with relapsing multiple sclerosis and primary progressive multiple sclerosis. 12 July 2024
Biotechnology
Canadian biotech Aspect Biosystems has received a $72.75 million investment from the Governments of Canada and British Columbia. 12 July 2024
Pharmaceutical
The global hormone replacement therapy (HRT) market, valued at $21 billion in 2023, is projected to grow to $38.8 billion by 2034. 12 July 2024
Biosimilars
India's Zydus Lifesciences has been barred by the Delhi High Court from selling its breast cancer drug, Sigrima, a biosimilar version of Roche's pertuzumab (brand name Perjeta). 12 July 2024
Biotechnology
The clinical trial landscape for chronic lymphocytic leukemia (CLL) shows a robust global effort to advance treatment options and understand the disease, according to a report. 12 July 2024
Biotechnology
The US Senate has unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150). 12 July 2024
Pharmaceutical
Shares of Texas, USA-based protein expert Salarius Pharmaceuticals fell more than 20% to $2.28 by close of trading on Thursday after the Food and Drug Administration (FDA) placed a study of the clinical-stage biopharmaceutical company's lead drug candidate on partial clinical hold. 12 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze